The Chronic Inflammatory Demyelinating Polyneuropathy market report also offers comprehensive insights into the Chronic Inflammatory Demyelinating Polyneuropathy market size, share, Chronic Inflammatory Demyelinating Polyneuropathy epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Chronic Inflammatory Demyelinating Polyneuropathy market size growth forward.
Some of the key highlights from the Chronic Inflammatory Demyelinating Polyneuropathy Market Insights Report:
Several key pharmaceutical companies, including CSL Behring, Grifols, Kedrion Biopharma, Nihon Pharmaceutical, LFB, Teijin Pharma, OctaPharma, Shire, Takeda, UCB Biopharma, MedDay Pharmaceuticals, GeNeuro Pharmaceuticals, Pfizer, argenx, Momenta Pharmaceuticals, and others, are developing novel products to improve the Chronic Inflammatory Demyelinating Polyneuropathy treatment outlook.
DelveInsight estimates that, in 2023, there were approximately 45,587 diagnosed cases of chronic inflammatory demyelinating polyneuropathy (CIDP) across the 7MM. Of these, the United States represented 66.3% of the cases, the EU4 and the UK accounted for nearly 29.2%, and Japan had 4.5%.
The CIDP market is expected to experience steady growth, with a strong compound annual growth rate (CAGR) anticipated from 2024 to 2034. This growth will be driven by the introduction of innovative therapies such as riliprubart, nipocalimab, and batoclimab.
According to DelveInsight’s analysis, the CIDP market in the 7MM was valued at approximately USD 1,780 million in 2023, and it is projected to expand at a CAGR of 7.2% from 2024 to 2034.
Key players in the CIDP market include Octapharma, Pfizer, CSL Behring, and Takeda, which offer approved treatments like HYQVIA in the US and EU, and PRIVIGEN in the US, EU, and Japan.
For some patients, treatments may fail to prevent disease progression or reduce frequent relapses, leading to potential disability. Moreover, there is a lack of approved therapies specifically designed for managing CIDP in patients who are prone to relapses. The off-label use of immunoglobulins limits the uptake of approved treatments like HIZENTRA and PRIVIGEN. Additionally, long-term use of corticosteroids or immunosuppressants raises the risk of infections, diabetes, and osteoporosis. In some cases, ineffective treatments fail to prevent relapses or slow disease progression, complicating the management of CIDP and resulting in disability.
As per DelveInsight analysis, the Chronic Inflammatory Demyelinating Polyneuropathy market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Chronic Inflammatory Demyelinating Polyneuropathy Market Landscape
Chronic Inflammatory Demyelinating Polyneuropathy Overview
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological condition marked by inflammation and damage to the myelin sheath, which is the protective covering of the nerves. This damage interferes with the transmission of signals between nerves and muscles, causing progressive weakness and sensory dysfunction.
CIDP can be categorized into typical and atypical forms. The typical form, which is the most common, involves symmetrical polyneuropathy, where both proximal and distal muscles are affected equally, leading to widespread weakness and sensory issues. Symptoms typically develop slowly, though their severity varies from patient to patient, affecting mobility, fine motor abilities, and daily tasks.
Atypical CIDP includes variants such as Multifocal Acquired Demyelinating Sensory and Motor Neuropathy (MADSAM) or asymmetric CIDP, where nerve damage occurs in specific areas rather than symmetrically. Another form, Distal Acquired Demyelinating Symmetric Neuropathy (DADS), primarily affects the lower limbs and progresses at a slower rate. CIDP can also target only motor or sensory nerves.
The outcome of CIDP is heavily influenced by early diagnosis and appropriate treatment. Many patients experience significant improvements or even remission with immunomodulatory therapies. However, some cases may not respond to treatment, leading to persistent disability, and a small number of patients may have a severe, progressive form of the disease despite ongoing therapy.
Do you know the treatment paradigms for different countries? Download our Chronic Inflammatory Demyelinating Polyneuropathy Market Sample Report
Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology Insights
Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology Segmentation
DelveInsight’s Chronic Inflammatory Demyelinating Polyneuropathy market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Chronic Inflammatory Demyelinating Polyneuropathy historical patient pools and forecasted Chronic Inflammatory Demyelinating Polyneuropathy patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Chronic Inflammatory Demyelinating Polyneuropathy Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:
Chronic Inflammatory Demyelinating Polyneuropathy Prevalence
Age-Specific Chronic Inflammatory Demyelinating Polyneuropathy Prevalence
Gender-Specific Chronic Inflammatory Demyelinating Polyneuropathy Prevalence
Diagnosed and Treatable Cases of Chronic Inflammatory Demyelinating Polyneuropathy
Visit for more @ Chronic Inflammatory Demyelinating Polyneuropathy Epidemiological Insights
Chronic Inflammatory Demyelinating Polyneuropathy Market Outlook
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare disease that has gained more attention due to improved diagnostics, greater awareness, and a better understanding of the condition. Treatment usually combines medications and supportive care, aiming to reduce inflammation, modulate the immune system, and enhance motor and sensory functions.
Corticosteroids like prednisone and dexamethasone are commonly used as initial treatments, but they come with significant long-term side effects such as osteoporosis, weight gain, and increased infection risk. These risks often require the addition of steroid-sparing agents, which may not work for all patients.
Plasma exchange has short-term benefits in removing harmful antibodies but is invasive and requires specialized centers. Intravenous immunoglobulin (IVIg) has become the preferred treatment for long-term disease management, though it is costly, time-consuming, and depends on donor plasma, raising concerns about availability.
Approved drugs for CIDP treatment focus on immune modulation, including PANZYGA, an immunoglobulin co-developed by Pfizer and Octapharma, and PRIVIGEN, an immunoglobulin offered by CSL Behring. PRIVIGEN is a room-temperature-stored, ready-to-use IVIg.
Chronic Inflammatory Demyelinating Polyneuropathy Emerging Drugs
Riliprubart (SAR445088): Sanofi
Nipocalimab: Janssen Research and Development
Batoclimab (HL161): Immunovant Sciences GmbH/HanAll Pharma/Roivant Sciences
HYQVIA (Immune Globulin Infusion 10% [Human] with Recombinant Human Hyaluronidase): Takeda
VYVGART HYTRULO (Efgartigimod Alfa and Hyaluronidase-Qvfc): Argenx
GAMMAGARD LIQUID/KIOVIG (Immune Globulin Infusion [Human] 10% Solution): Takeda
Chronic Inflammatory Demyelinating Polyneuropathy Key Companies
CSL Behring, Grifols, Kedrion Biopharma, Nihon Pharmaceutical, LFB, Teijin Pharma, OctaPharma, Shire, Takeda, UCB Biopharma, MedDay Pharmaceuticals, GeNeuro Pharmaceuticals, Pfizer, argenx, Momenta Pharmaceuticals, and others
For more information, visit Chronic Inflammatory Demyelinating Polyneuropathy Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Chronic Inflammatory Demyelinating Polyneuropathy Market Report:
11 Years Forecast
7MM Coverage
Descriptive overview of Chronic Inflammatory Demyelinating Polyneuropathy, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Chronic Inflammatory Demyelinating Polyneuropathy epidemiology in the 7MM
Chronic Inflammatory Demyelinating Polyneuropathy marketed and emerging therapies
Chronic Inflammatory Demyelinating Polyneuropathy companies
Chronic Inflammatory Demyelinating Polyneuropathy market drivers and barriers
Table of Contents:
1 Chronic Inflammatory Demyelinating Polyneuropathy Market Key Comprehensive Insights
2 Chronic Inflammatory Demyelinating Polyneuropathy Market Report Introduction
3 Competitive Intelligence Analysis for Chronic Inflammatory Demyelinating Polyneuropathy
4 Chronic Inflammatory Demyelinating Polyneuropathy Market Analysis Overview at a Glance
5 Executive Summary of Chronic Inflammatory Demyelinating Polyneuropathy
6 Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology and Market Methodology
7 Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology and Patient Population
8 Chronic Inflammatory Demyelinating Polyneuropathy Patient Journey
9 Chronic Inflammatory Demyelinating Polyneuropathy Treatment Algorithm, Chronic Inflammatory Demyelinating Polyneuropathy Current Treatment, and Medical Practices
10 Key Endpoints in Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trials
11 Chronic Inflammatory Demyelinating Polyneuropathy Marketed Therapies
12 Chronic Inflammatory Demyelinating Polyneuropathy Emerging Therapies
13 Chronic Inflammatory Demyelinating Polyneuropathy: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Chronic Inflammatory Demyelinating Polyneuropathy
16 Chronic Inflammatory Demyelinating Polyneuropathy Market Key Opinion Leaders Reviews
18 Chronic Inflammatory Demyelinating Polyneuropathy Market Drivers
19 Chronic Inflammatory Demyelinating Polyneuropathy Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology 2034
DelveInsight’s “Chronic Inflammatory Demyelinating Polyneuropathy – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Chronic Inflammatory Demyelinating Polyneuropathy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Chronic Inflammatory Demyelinating Polyneuropathy Pipeline 2024
“Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chronic Inflammatory Demyelinating Polyneuropathy market. A detailed picture of the Chronic Inflammatory Demyelinating Polyneuropathy pipeline landscape is provided, which includes the disease overview and Chronic Inflammatory Demyelinating Polyneuropathy treatment guidelines.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
